Pfizer Inc. (NYSE:PFE) Shares Purchased by Sargent Investment Group LLC

Sargent Investment Group LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,093 shares of the biopharmaceutical company’s stock after buying an additional 536 shares during the quarter. Sargent Investment Group LLC’s holdings in Pfizer were worth $217,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Old North State Wealth Management LLC grew its holdings in Pfizer by 23.6% during the 4th quarter. Old North State Wealth Management LLC now owns 79,441 shares of the biopharmaceutical company’s stock valued at $2,109,000 after buying an additional 15,194 shares during the last quarter. James J. Burns & Company LLC grew its holdings in Pfizer by 4.2% during the 4th quarter. James J. Burns & Company LLC now owns 14,912 shares of the biopharmaceutical company’s stock valued at $396,000 after buying an additional 605 shares during the last quarter. Stephens Consulting LLC grew its holdings in Pfizer by 66.1% during the 4th quarter. Stephens Consulting LLC now owns 5,826 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 2,318 shares during the last quarter. Brown Lisle Cummings Inc. grew its holdings in Pfizer by 6.7% during the 4th quarter. Brown Lisle Cummings Inc. now owns 61,308 shares of the biopharmaceutical company’s stock valued at $1,626,000 after buying an additional 3,824 shares during the last quarter. Finally, Commonwealth Financial Services LLC boosted its holdings in shares of Pfizer by 139.5% during the fourth quarter. Commonwealth Financial Services LLC now owns 35,063 shares of the biopharmaceutical company’s stock worth $930,000 after purchasing an additional 20,421 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PFE. Sanford C. Bernstein began coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Citigroup decreased their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, UBS Group decreased their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Trading Up 2.3 %

NYSE:PFE opened at $26.46 on Thursday. The business’s 50-day moving average is $26.27 and its two-hundred day moving average is $27.79. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The firm has a market capitalization of $149.94 billion, a PE ratio of 35.76, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the company posted $0.10 earnings per share. The firm’s revenue was up 24.7% compared to the same quarter last year. Research analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.50%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s payout ratio is presently 232.44%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.